| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| SCYNEXIS INC | Chief Executive Officer, Director | Common Stock | 272,068 | $816,204 | $3.00 | 26 Apr 2022 | Direct |
| Aquestive Therapeutics, Inc. | Director | Stock Option (Right to Purchase) | 42,000 | $143,220 | $3.41 | 11 Jun 2025 | Direct |
| SCYNEXIS INC | Chief Executive Officer, Director | Common Stock Warrant | 75,000 | 26 Apr 2022 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| AQST | Aquestive Therapeutics, Inc. | 11 Jun 2025 | 1 | +$143,220 | 4 | Director | 12 Jun 2025, 13:57 |
| AQST | Aquestive Therapeutics, Inc. | 20 Jun 2024 | 1 | $0 | 4 | Director | 21 Jun 2024, 13:51 |
| AQST | Aquestive Therapeutics, Inc. | 21 Jun 2023 | 1 | $0 | 4 | Director | 23 Jun 2023, 12:26 |
| AQST | Aquestive Therapeutics, Inc. | 22 Jun 2022 | 1 | $0 | 4 | Director | 24 Jun 2022, 16:22 |
| SCYX | SCYNEXIS INC | 26 Apr 2022 | 2 | +$225,000 | 4 | Chief Executive Officer, Director | 28 Apr 2022, 07:25 |
| SCYX | SCYNEXIS INC | 04 Feb 2022 | 2 | $0 | 4 | Chief Executive Officer, Director | 08 Feb 2022, 15:14 |
| AQST | Aquestive Therapeutics, Inc. | 15 Jun 2021 | 1 | $0 | 4 | Director | 17 Jun 2021, 18:51 |